bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate profile

bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate: an antioxidant and antidiabetic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11272241
SCHEMBL ID	755468
MeSH ID	M0517945

Synonym
decanedioic acid, 1,10-bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) ester
19r5n3wr4n ,
unii-19r5n3wr4n
iacvita
bis-(tetramethyl hydroxypiperidinyl) sebacate
sebacic acid, bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) ester
30538-92-2
decanedioic acid, bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) ester
bis-(tetramethyl hydroxypiperidinyl) sebacate [inci]
bis(1-oxyl--2,2,6,6-tetramethylpiperidin-4-yl) sebacate
bis(1-oxyl--2,2,6,6-tetramethylpiperidin4-yl) sebacate
bis(1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)sebacate
bis(1-oxyl-2,2,6,6tetramethylpiperidin-4-yl) sebacate
bis(1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl) sebacate
bis(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) sebacate
bis(1-oxyl-2,2,6,6-tetramethylpiperidin4-yl) sebacate
bis(1-oxyl-2,2,6,6tetramethylpiperidin-4-yl)sebacate
bis(1-oxyl-2,2,6,6-tetramethylpiperidin-4-y) sebacate
di-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) sebacate
SXPLGYBFGPYAHS-UHFFFAOYSA-N
SCHEMBL755468
DTXSID20184619
bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate
Q27252127
D89153
AS-83792

Excerpt	Reference
" Multiple mechanisms concur in generating the damage, but activation of oxidative stress may contribute to the final toxic effect."	( The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. Boggi, U; Bonamassa, B; Canistro, D; D'Aleo, V; Del Guerra, S; Del Prato, S; Filipponi, F; Lupi, R; Martano, M; Paolini, M; Soleti, A; Valgimigli, L, 2009)

Excerpt	Reference
" Oral administration of IAC dosed at 50 and 100 mg/kg was able to significantly prevent gastric ulceration induced by indomethacin and by stress."	( Further evidence of the antiulcer activity of IAC, a novel free radical scavenger. Baraldi, M; Carnevale, G; Zanoli, P; Zavatti, M, 2011)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (42.86)	29.6817
2010's	8 (57.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (7.14%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (92.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.13	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.45	2	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.13	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.77	3	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
stearic acid octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.	2.13	1	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.96	4	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
dinitrofluorobenzene Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.	2.05	1	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.96	4	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
2,4-dinitrofluorobenzene sulfonic acid [no description available]	2.05	1
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.05	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
piperidines Piperidines: A family of hexahydropyridines.	5.17	14

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.45	7
Innate Inflammatory Response [description not available]	3.4	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.4	2
Gastric Ulcer [description not available]	2.46	2
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.46	2
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.46	2
Anterior Cerebral Circulation Infarction [description not available]	2.05	1
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	2.05	1
Cerebral Ischemia [description not available]	2.05	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.05	1
Carotid Artery Narrowing [description not available]	2.05	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.05	1
Carotid Stenosis Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)	2.05	1
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	2.05	1
Alloxan Diabetes [description not available]	2.45	2
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.45	2
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.45	2
Anasarca [description not available]	2.06	1
Foreign-Body Granuloma [description not available]	2.06	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.06	1
Amyloid Deposits [description not available]	2.06	1
Acute Confusional Senile Dementia [description not available]	2.06	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.06	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.03	1
Impaired Glucose Tolerance [description not available]	2.03	1
Diabetes Mellitus, Adult-Onset [description not available]	2.03	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.03	1
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.03	1
Anterior Choroidal Artery Infarction [description not available]	2.04	1
Anterior Circulation Transient Ischemic Attack [description not available]	2.04	1
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	2.04	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.04	1

bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate

Description

Cross-References

Synonyms (26)

Toxicity

Dosage Studied

Research

Studies (14)

Study Types

bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate

Description

Cross-References

Synonyms (26)

Toxicity

Dosage Studied

Research

Studies (14)

Study Types

Related Drugs (11)

Related Conditions (32)